Final approval from USFDA for Leuprolide Acetate injection - Zydus Lifesciences Ltd

BSE: 532321 NSE:

Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer. Leuprolide Acetate injections will be manufactured at the Company’s oncology injectable manufacturing facility at SEZ1, Ahmedabad (‘ALIDAC’). Leuprolide Acetate injection had annual sales of USD 69 mn in the United States (IQVIA MAT Sept2025).